Genzyme/Isis’ Mipomersen Development Outlook Pricier And Riskier After FDA Weighs In
This article was originally published in The Pink Sheet Daily
Executive Summary
Cardiotoxicity and outcomes requirements push back NDA timeline for the novel LDL-lowering drug.
You may also be interested in...
Top Ten Unpartnered Drugs: It's Tough To Make The Grade In CVD/Metabolics
Early-stage talent parade will be held at Windhover's Therapeutic Area Partnerships conference next week.
Top Ten Unpartnered Drugs: It's Tough To Make The Grade In CVD/Metabolics
Early-stage talent parade will be held at Windhover's Therapeutic Area Partnerships conference next week.
GSK Goes To The Heart Of The Problem With Outcomes Study For Darapladib
GlaxoSmithKline is applying a lesson the pharmaceutical industry learned from recent events in cardiovascular drug development: do an outcomes study, and start it early